导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.71% | 1568/4773 |
| 近一周 | -1.02% | 1526/5465 |
| 近一月 | -1.27% | 1089/5421 |
| 近一季 | -8.19% | 3155/5231 |
| 近半年 | -4.56% | 2863/4920 |
| 近一年 | 5.97% | 1642/4394 |
| 近两年 | 87.47% | 743/2954 |
| 近三年 | 43.92% | 669/2253 |
| 成立以来 | 77.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.25% 1333/4961 |
12.72% 2135/5312 |
- - |
- - |
| 2025 | 31.73% 1218/4813 |
5.80% 728/3635 |
4.50% 746/4076 |
16.74% 2609/4524 |
2.07% 1090/4813 |
| 2024 | 6.08% 1788/3463 |
-6.48% 2057/2808 |
-8.89% 2299/3014 |
14.15% 2039/3129 |
9.06% 350/3463 |
| 2023 | -6.41% 841/2656 |
6.44% 686/2280 |
-5.65% 1511/2385 |
-5.21% 1291/2515 |
-1.69% 358/2655 |
| 2022 | -23.61% 1153/2207 |
-17.41% 1206/1919 |
7.50% 461/2016 |
-14.77% 1145/2113 |
0.96% 1419/2208 |
| 2021 | 10.79% 417/1822 |
-4.61% 877/1255 |
10.79% 435/1330 |
-1.84% 544/1466 |
6.79% 201/1822 |
| 2020 | 36.19% 401/1250 |
-2.12% 254/1028 |
20.76% 261/1067 |
7.82% 760/1164 |
6.86% 739/1184 |
| 2019 | 33.44% 432/1092 |
31.82% 188/754 |
-10.11% 715/804 |
3.34% 258/850 |
8.97% 267/918 |
| 2018 | -34.58% 572/834 |
- - |
- - |
- - |
-14.24% 572/691 |
| 2017 | 5.84% 340/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.55% 421/605 |
- - |
- - |
- - |
- - |
| 2015 | 44.79% 32/575 |
- - |
- - |
- - |
- - |
| 2014 | 14.40% 201/237 |
- - |
- - |
- - |
- - |
| 2013 | 21.60% 14/186 |
- - |
- - |
- - |
- - |
| 2012 | -2.85% 134/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发国证2000ETF联接A VS. 长安沪深300非周期A(740101) |